How Are the New Lupus Nephritis Guidelines Impacting Treatment?
Perspective by renowned nephrologist Dr. Brad Rovin Recognized as National Kidney Month, March is the ideal time to learn more...
Brad Rovin
Independent Panel Gives High Marks to New Lupus Nephritis Therapies, Policies Reflect LRA Feedback
April 20, 2021
At a public meeting in March led by the Institute for Clinical and Economic Review (ICER), an...
Join LRA March 11 to Learn What’s New in Lupus Nephritis
What’s New in Lupus Nephritis? A Research & Treatment Update
A Learn from Lupus Webcast
Lupus nephritis is a common and dangerous...
LRA Pleased to Share GSK’s Benlysta® (belimumab) is First Lupus Nephritis Treatment Approved by FDA
NEW YORK, NY. December 17, 2020. The Lupus Research Alliance (LRA) congratulates GSK on the U.S. Food and Drug...
LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis
September 16, 2020
NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s...
The Lupus Research Alliance Partners with the National Kidney Foundation to Offer Course to Healthcare Professionals
November 12, 2019
The Lupus Research Alliance (LRA) is pleased to announce a new collaboration with the National Kidney Foundation...
Lupus Research Alliance Response to Positive Trial Testing Obinutuzumab (Gazyva®) for Lupus Nephritis
NEW YORK, Nov. 10, 2019 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to acknowledge positive results presented by...